- Home
- ELEV vs RVPH Comparison
ELEV vs RVPH Comparison
Compare ELEV & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- RVPH
- Stock Information
- Founded
- ELEV 2019
- RVPH 2006
- Country
- ELEV United States
- RVPH United States
- Employees
- ELEV N/A
- RVPH N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- RVPH Health Care
- Exchange
- ELEV Nasdaq
- RVPH Nasdaq
- Market Cap
- ELEV 34.0M
- RVPH 33.4M
- IPO Year
- ELEV 2021
- RVPH N/A
- Fundamental
- Price
- ELEV $0.61
- RVPH $1.24
- Analyst Decision
- ELEV Strong Buy
- RVPH Strong Buy
- Analyst Count
- ELEV 5
- RVPH 4
- Target Price
- ELEV $7.80
- RVPH $15.33
- AVG Volume (30 Days)
- ELEV 673.9K
- RVPH 656.8K
- Earning Date
- ELEV 11-06-2024
- RVPH 11-14-2024
- Dividend Yield
- ELEV N/A
- RVPH N/A
- EPS Growth
- ELEV N/A
- RVPH N/A
- EPS
- ELEV N/A
- RVPH N/A
- Revenue
- ELEV N/A
- RVPH N/A
- Revenue This Year
- ELEV N/A
- RVPH N/A
- Revenue Next Year
- ELEV N/A
- RVPH N/A
- P/E Ratio
- ELEV N/A
- RVPH N/A
- Revenue Growth
- ELEV N/A
- RVPH N/A
- 52 Week Low
- ELEV $0.44
- RVPH $0.60
- 52 Week High
- ELEV $5.83
- RVPH $5.67
- Technical
- Relative Strength Index (RSI)
- ELEV 51.53
- RVPH 54.13
- Support Level
- ELEV $0.52
- RVPH $1.09
- Resistance Level
- ELEV $0.70
- RVPH $1.37
- Average True Range (ATR)
- ELEV 0.06
- RVPH 0.15
- MACD
- ELEV 0.00
- RVPH 0.03
- Stochastic Oscillator
- ELEV 41.81
- RVPH 63.16
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.